Research Progress on Elesclomol-Induced Cuproptosis for Antitumor Effects

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cuproptosis is a novel cell death pathway involving copper ions and the mitochondrial tricarboxylic acid cycle.
• Elesclomol is a small molecule that carries copper ions into mitochondria.

Purpose of the Study:

• To investigate the mechanism of elesclomol-induced cuproptosis and its therapeutic potential in cancer.
• To explore resistance mechanisms and combination strategies for elesclomol therapy.

Main Methods:

• Investigated the role of ferredoxin-1 (FDX1) in elesclomol-induced protein aggregation and cell death.
• Assessed the impact of elesclomol on the tumor immune microenvironment, including dendritic cell maturation and T cell infiltration.
• Analyzed resistance mechanisms involving hypoxia-inducible factor-1α (HIF-1α) and the Nrf2 pathway.
• Evaluated combination therapies with ferroptosis inducers and chemotherapeutic drugs.

Main Results:

• Elesclomol induces cuproptosis by causing lipoylated protein aggregation and iron-sulfur cluster loss via FDX1.
• Elesclomol enhances anti-tumor immunity by promoting dendritic cell maturation and CD8+ T cell infiltration, synergizing with immune checkpoint inhibitors.
• Tumor cells develop resistance through HIF-1α and Nrf2-mediated metabolic reprogramming.
• Combination therapies with elesclomol show significant antitumor effects.

Conclusions:

• Elesclomol represents a promising therapeutic agent for cancer by inducing cuproptosis and modulating the tumor immune microenvironment.
• Overcoming resistance through combination therapies and developing precise biomarkers and nanodelivery systems are crucial for clinical translation.